Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have signed a consent form before any trial-related procedures begin.
• People who are 18 years of age or older at the time of signing the consent form.
• People who have a reasonable level of physical functioning (rated on a standard scale from 0 to 2) and whose condition has not gotten worse in the past 2 weeks.
• People who are expected to live for at least 3 months.
• People who have been diagnosed with a specific type of T-cell lymphoma (called peripheral T-cell lymphoma, or PTCL) confirmed by tissue testing, and who have not yet received any treatment for it. The specific subtypes included are: PTCL-NOS, AITL, FTCL, nodular PTCL with TFH phenotype, ALK-negative ALCL, ALK-positive ALCL, EATL, MEITL, HSTCL, and SPTCL (confirm with trial site if unsure which subtype applies).
• People whose bone marrow and major organs are functioning well enough to meet the trial's requirements.
• People whose heart is pumping blood at 50% or more of its normal capacity, as measured by an ultrasound of the heart.
• People who are willing and able to follow all study procedures as required by the protocol.
• People who are willing to use adequate birth control during treatment and for a set period afterward.

Who may not be able to join:

• People who have already received treatment for PTCL, except for short-term steroid use (7 days or fewer at a low dose), or who have had radiation therapy beyond a limited local area.
• People who are currently receiving any other cancer treatment or experimental therapy.
• People who have previously received high cumulative doses of certain chemotherapy drugs called anthracyclines (such as doxorubicin, epirubicin, or similar) above specified limits.
• People who have had major surgery or serious physical injury within 4 weeks before starting the trial, or who are expected to need major surgery during the trial.
• People who have previously been treated with JAK or STAT3 inhibitor medications after their PTCL diagnosis.
• People who have received a live vaccine within 28 days before joining the trial.
• People who are currently taking blood thinners, antiplatelet medications, or vitamin K antagonists and cannot stop taking them at least 1 week before starting the trial.
• People who are taking certain medications or herbal supplements that strongly affect how the body processes drugs (known as potent CYP3A inhibitors or inducers, or certain other drug interaction categories) and cannot stop them at least 1 week before starting the trial (confirm with trial site for the full list).
• People who have signs or scan results suggesting the lymphoma has spread to the brain or the lining around the brain or spinal cord.
• People with serious lung problems, active lung inflammation, or a history of significant lung disease requiring steroid treatment.
• People who currently need treatment with immune-suppressing drugs, biological medicines, or anti-inflammatory drugs (NSAIDs).
• People who have an active infection at the time of enrollment.
• People with significant heart problems.
• People who have had another cancer in the past 3 years, although some fully treated non-aggressive skin cancers or cervical conditions may be considered on a case-by-case basis.
• People with ongoing nausea, vomiting, serious gut disease, difficulty swallowing, or who have had major bowel surgery that could affect how the study drug is absorbed.
• People who are currently breastfeeding.
• People who have had a serious allergic reaction to the study drug (golidocitinib) or to any component of the CHOP chemotherapy regimen used in this trial.
• People with poorly controlled high blood pressure, active bleeding problems, or other serious uncontrolled health conditions, as determined by the trial doctor.
• People with a medical, psychological, or other condition that the trial doctor believes could affect their safety or their ability to follow the study protocol.
• People with personal, family, social, or location-related circumstances that would make it difficult to take part consistently or that could make the study results hard to interpret.
• People who are involved in planning or running this trial.

Important: Always verify eligibility with the trial site directly before applying.